Welcome to ScreenCell
ScreenCell® is a non-invasive technology for isolation of Circulating Rare Cells (CRCs) from whole blood, and potentially any atypical cell in biological fluids. By providing an easy access to fixed or live Circulating Tumor Cells (CTCs) and Circulating Tumor Microemboli (CTMs), the ScreenCell devices allows a full range access to phenotypical, genotypical, and functional characterization of these cells and many basic researchers and clinical oncologists use the ScreenCell devices to better understand the value of circulating tumor cells in patients with established malignant diseases. By becoming a trusted associate in biomedical research, ScreenCell wish to contribute to a non-invasive evaluation of specific therapeutic targets with an aim at developing a “real time” monitoring of target evolution under the pressure of targeted therapies in cancer and becoming a companion device for the development for new drugs development. ScreenCell wish also to allow a better understanding of the functional significance of CTCs and CTMs in terms of prognosis and evolution of malignant diseases. The ScreenCell devices can also be used to isolate Circulating Fetal Cells in maternal peripheral blood with an aim at developing a new non-invasive approach to prenatal diagnosis.
To help you find the right ScreenCell filtration device for your research work, please go to the Web portals corresponding to your specific needs:
|– Isolating fixed CRCs
– Isolating live CRCs for cell culture
– Isolating live CRCs for molecular biology